Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JK1201I in HER2-negative breast cancer with brain metastases
CTR20243210Phase 2Active
- Sponsor
- JenKem Technology
- Start
- Nov 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of JK-1201I in breast cancer, triple-negative breast cancer (TNBC), hormone receptor-positive/HER2-negative breast cancer, sponsored by JenKem Technology. Started Nov 2024; status: active.
02
Drugs
JK-1201I
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on CTR20243210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243210.